BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Opko Health Provides Commercial Update For RAYALDEE

  June 5, 2017

   · 

  6 min read
• Drug Development

  Celldex Presents Promising Overall Survival Data From Phase II Study Of Single-Agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma

  June 5, 2017

   · 

  9 min read
• Drug Development

  Eisai Inc. Release: Lenvatinib Demonstrates Positive Results Vs Sorafenib Across All Endpoints In First-Line Phase III Non-Inferiority Trial Of Unresectable Hepatocellular Carcinoma (uHCC)

  June 5, 2017

   · 

  15 min read
• Drug Development

  Amgen Presents New Phase II Data On IMLYGIC (Talimogene Laherparepvec) Investigational Combination At ASCO 2017

  June 5, 2017

   · 

  16 min read
• Drug Development

  CARsgen Therapeutics Presents Phase I Results Of CAR-GPC3 T HCC Trial At ASCO 2017 Annual Meeting

  June 5, 2017

   · 

  2 min read
• Drug Development

  Blueprint Medicines Announces New Phase I Clinical Data For BLU-285 In Advanced Gastrointestinal Stromal Tumors And Plans To Pursue Expedited Development In Patients With A PDGFRa D842V Mutation

  June 5, 2017

   · 

  16 min read
• Drug Development

  Incyte Release: Clinical Trial Data For Combination Of Epacadostat And Opdivo (Nivolumab) Demonstrate Durable Clinical Responses In Patients With Melanoma And Head And Neck Cancer

  June 5, 2017

   · 

  1 min read
• Drug Development

  Boston Biomedical Presents Data Suggesting Anti-Cancer Activity Of Investigational Stemness Inhibitor Napabucasin In Seven Tumor Types At ASCO 2017

  June 5, 2017

   · 

  11 min read
• Zenith Technologies Announces Issuance Of Patent For ZEN-3694 And Presentation Details At BIO International Convention

  June 5, 2017

   · 

  1 min read
• Drug Development

  Bristol-Myers Squibb Release: Early, Durable Responses Seen With Sprycel (Dasatinib) In First- And Second-Line Treatment Of Pediatric Patients With Chronic Myeloid Leukemia In Chronic Phase (CP-CML)

  June 5, 2017

   · 

  2 min read